ValuEngine upgraded shares of MacroGenics (NASDAQ:MGNX) from a strong sell rating to a sell rating in a report issued on Friday.

MGNX has been the subject of a number of other reports. Stifel Nicolaus reissued a buy rating and issued a $34.00 price target on shares of MacroGenics in a research report on Tuesday, September 12th. SunTrust Banks reissued a buy rating and issued a $26.00 price target on shares of MacroGenics in a research report on Friday, September 1st. Zacks Investment Research cut shares of MacroGenics from a hold rating to a sell rating in a research report on Wednesday, October 4th. BidaskClub raised shares of MacroGenics from a strong sell rating to a sell rating in a report on Friday, August 25th. Finally, Morgan Stanley reduced their target price on shares of MacroGenics from $22.00 to $21.00 and set an equal weight rating for the company in a report on Monday, August 7th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company. MacroGenics presently has an average rating of Buy and an average target price of $30.10.

Shares of MacroGenics (NASDAQ MGNX) traded up $0.07 on Friday, reaching $19.39. 354,471 shares of the company were exchanged, compared to its average volume of 238,964. MacroGenics has a 52-week low of $14.36 and a 52-week high of $28.48.

MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.19). MacroGenics had a negative net margin of 1,526.55% and a negative return on equity of 69.31%. The company had revenue of $1.70 million during the quarter, compared to analysts’ expectations of $5.50 million. During the same period last year, the firm earned ($0.97) earnings per share. MacroGenics’s revenue was down 48.5% on a year-over-year basis. equities analysts predict that MacroGenics will post -0.7 EPS for the current year.

In other news, SVP Jon Marc Wigginton sold 10,000 shares of the company’s stock in a transaction dated Wednesday, October 25th. The shares were sold at an average price of $20.00, for a total value of $200,000.00. Following the completion of the sale, the senior vice president now directly owns 40,000 shares of the company’s stock, valued at $800,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 8.30% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Point72 Asset Management L.P. raised its holdings in MacroGenics by 8.9% during the third quarter. Point72 Asset Management L.P. now owns 1,181,317 shares of the biopharmaceutical company’s stock worth $21,831,000 after purchasing an additional 96,900 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its holdings in MacroGenics by 43.9% during the third quarter. Cornerstone Capital Management Holdings LLC. now owns 33,438 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 10,200 shares in the last quarter. Granite Point Capital Management L.P. purchased a new position in MacroGenics during the third quarter worth about $756,000. Pinnacle Associates Ltd. raised its holdings in MacroGenics by 38.3% during the third quarter. Pinnacle Associates Ltd. now owns 843,175 shares of the biopharmaceutical company’s stock worth $15,582,000 after purchasing an additional 233,657 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in MacroGenics by 56.9% during the third quarter. Dimensional Fund Advisors LP now owns 283,517 shares of the biopharmaceutical company’s stock worth $5,239,000 after purchasing an additional 102,778 shares in the last quarter. 85.81% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “MacroGenics (MGNX) Upgraded to Sell by ValuEngine” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/12/02/macrogenics-mgnx-upgraded-to-sell-by-valuengine.html.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

Receive News & Stock Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related stocks with our FREE daily email newsletter.